Can evidence drive the development of a sound national EPO reimbursement policy?

American Journal of Kidney Diseases

Volumn 41, Issue 1, 2003, Pages 254-258

  Wish, Jay B ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; DOSE RESPONSE; EDITORIAL; HEALTH CARE FINANCING; HEALTH CARE QUALITY; HEART DISEASE; HEMATOCRIT; HEMODIALYSIS; HEMOGLOBIN DETERMINATION; HUMAN; HYDRATION; KIDNEY FAILURE; LABORATORY TEST; MEDICARE; PERITONEAL DIALYSIS; POPULATION; PRACTICE GUIDELINE; QUALITY CONTROL; REIMBURSEMENT; TREATMENT OUTCOME;

EID: 0037228477     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/ajkd.2003.50067     Document Type: Editorial

References (17)

1. McClellan WM, Helgerson SD, Frederick PR, et al: Implementing the health care quality improvement program in the Medicare ESRD program: A new era of quality improvement in ESRD. Adv Ren Replace Ther 2:89-94, 1995
2. Health Care Financing Administration: 1998 Annual Report, End Stage Renal Disease Core Indicators Project. Baltimore, MD, Department of Health and Human Services, Health Care Financing Administration. Health Standards and Quality Bureau, 1998
3. Centers for Medicare and Medicaid Services: 2001 Annual Report, End Stage Renal Disease Clinical Performance Measures Project. Baltimore, MD, Department of Health and Human Services, Centers for Medicare and Medicaid Services, Center for Beneficiary Choices, 2001 (2001 data obtained from personal communication with CMS)
4. Eggers PW, Greer J, Jencks S: The use of Health Care Financing Administration data for the development of a quality improvement project on the treatment of anemia. Am J Kidney Dis 24:247-254, 1994
5. Besarab A, Bolton WK, Browne JK, et al: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339:584-590, 1998
6. Ma JZ, Ebben J, Xia H, Collins AJ: Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 10:610-619, 1999
7. Li S, Ebben J, Chen S, Collins AJ: Higher hematocrit values under K/DOQI guidelines are associated with lower mortality in incident dialysis patients. J Am Soc Nephrol 13:38A, 2002
8. Collins A, St Peter WL, Li SY, et al: Hematocrit levels 36-<39% are associated with lower hospitalization risk in Medicare hemodialysis patients. J Am Soc Nephrol 11:262A, 2000
9. Moreno F, Sanz-Guajardo D, Lopez-Gomes JM, et al: Increasing hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. J Am Soc Nephrol 11:335-342, 2000
10. Flamm CR, Aronson N, Bohn R, et al: Use of Epoetin for Anemia in Chronic Renal Failure. Evidence Report/Technology Assessment No. 29 (Prepared by the Blue Cross and Blue Shield Association Technology Evaluation Center under Contract No. 290-97-0015). AHRQ Publication No. 01-E016. Rockville, MD, Agency for Healthcare Research and Quality, 2001
11. Lacson E Jr, Ofsthun N, Lazarus JM: Effect of variability in anemia management on hemoglobin outcomes in ESRD. Am J Kidney Dis 41:111-124, 2003
12. Brier ME, Aronoff GR: Hemoglobin goals and the natural variability in the erythropoietin response. J Am Soc Nephrol 13:628A. 2002
13. Hirth RA, Wolfe RA, Wheeler JRC, et al: The ability of case mix to predict Medicare payments for EPO. J Am Soc Nephrol 13:615A, 2002
14. Pisoni RL: Erythropoietin therapy in Europe: Results from the DOPPS. Contrib Nephrol 137:396-402, 2002
15. Besarab A, Reyes CM, Hornberger J: Meta-analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patients. Am J Kidney Dis 40:439-446, 2002
16. Meyer KB, Kassirer JP: Squeezing more cost and care out of dialysis: Our patients would pay the price (editorial). Am J Med 112:232-234, 2002
17. Levin A: Preaching and practice: Evidence-based medicine and the accountability of nephrologists within the health care system. The implications and findings of the cost-saving potential of subcutaneous versus intravenous epoetin therapy (editorial). Am J Kidney Dis 40:662-663, 2002